Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.77 |
| ▸ | MAPT | P10636 | 4/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.77 |
| ▸ | GSK3B | P49841 | 6/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.61 |
| ▸ | CLK2 | P49760 | 3/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.61 |
| ▸ | CDC7 | O00311 | 2/20 | 0.61 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.61 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.61 |
| ▸ | PIM1 | P11309 | 2/20 | 0.61 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.61 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.61 |
| ▸ | GSK3A | P49840 | 2/20 | 0.61 |
| ▸ | NEK4 | P51957 | 2/20 | 0.61 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.61 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.61 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9252149 | 1.00 | MEN1 (0.77) | MEN1KMT2AMAPTALDH1A1GSK3B | |
| SCHEMBL15421749 | 1.00 | MEN1 (0.77) | MEN1KMT2AMAPTALDH1A1GSK3B | |
| SCHEMBL15421733 | 0.89 | GSK3B (0.61) | MEN1KMT2AMAPTALDH1A1GSK3B | |
| SCHEMBL15421732 | 0.89 | GSK3B (0.61) | MEN1KMT2AMAPTALDH1A1GSK3B | |
| SCHEMBL15421730 | 0.89 | GSK3B (0.61) | MEN1KMT2AMAPTALDH1A1GSK3B | |
| SCHEMBL30019922 | 0.87 | KMT2A (1.00) | MEN1KMT2AMAPTALDH1A1GSK3B | |
| SCHEMBL13848480 | 0.87 | KMT2A (1.00) | MEN1KMT2AMAPTALDH1A1GSK3B | |
| SCHEMBL15421424 | 0.87 | GSK3B (0.70) | MEN1KMT2AMAPTALDH1A1GSK3B | |
| SCHEMBL3125849 | 0.87 | GSK3B (0.70) | MEN1KMT2AMAPTALDH1A1GSK3B | |
| SCHEMBL3125853 | 0.87 | GSK3B (0.70) | MEN1KMT2AMAPTALDH1A1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160102065-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2016-04-14 | — | — | US | claimed |
| US-9896421-B2 | Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use thereof | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2018-02-20 | — | — | US | disclosed |
| US-20160102065-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2016-04-14 | — | — | US | disclosed |
| US-9216148-B2 | Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use therefor | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2015-12-22 | — | — | US | disclosed |
| US-20140023603-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2014-01-23 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| US-5464856-A | Arylmethylenyl derivatives of imidazolidinones useful as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1995-11-07 | — | — | US | disclosed |
| US-5306822-A | Mono-, di- or tri-methoxyphenylmethylene-2-thioxo-4-oxazolidinone as antihistamines | WARNER-LAMBERT COMPANY (US) | 1994-04-26 | — | — | US | disclosed |
| EP-0565135-A1 | Known and selected novel arylmethylenyl derivatives of imidazolidinones useful as antiallergy agents and antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1993-10-13 | — | — | EP | disclosed |
| US-5208250-A | Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents | WARNER-LAMBERT COMPANY (US) | 1993-05-04 | — | — | US | disclosed |
| EP-0343643-A2 | Arylmethylenyl derivatives of thiazolidnones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflamatory agents | WARNER-LAMBERT COMPANY (US) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140023603-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR | PPARG, PPARA, PPARD | MEN1 4685/4885KMT2A 3139/4885MAPT 2700/4885 |
| US-20160102065-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PPARG, PPARA, TYR | MEN1 4838/4885KMT2A 2641/4885MAPT 1956/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | MEN1 912/4885KMT2A 4327/4885MAPT 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.